The group's principal activity is to develop immunotherapeutics to treat and eradicate cancer and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection. The group's technologies are based on an understanding of the function of a protein 'pump' within cells that is essential in the processing of tumor antigens, known as tap. The group currently has none of its product candidates on the market and is focusing on the development and testing of its product candidates. The group has operations in Canada and United States.
Executive Information
Name
Title
Email
Alan Lindsay
Chmn.
N/A
Denis Corin
CEO, Pres.
N/A
Patrick McGowan
Sec., Treasurer, CFO, Principal Accounting Officer
